Cargando…

Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine Response

Introduction: Belatacept is a common immunosuppressive therapy used after kidney transplantation (KT) to avoid calcineurin-inhibitor (CNI) use and its related toxicities. It is unclear whether its use exposes KT recipients (KTx) to a greater risk of infection or a poorer response to vaccines. Areas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terrec, Florian, Jouve, Thomas, Malvezzi, Paolo, Janbon, Bénédicte, Naciri Bennani, Hamza, Rostaing, Lionel, Noble, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585113/ https://www.ncbi.nlm.nih.gov/pubmed/34768680 http://dx.doi.org/10.3390/jcm10215159

Ejemplares similares

Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters
por: Terrec, Florian, et al.
Publicado: (2019)

Protocol Biopsies on de novo Renal-Transplants at 3 Months after Surgery: Impact on 5-Year Transplant Survival
por: Terrec, Florian, et al.
Publicado: (2021)

Kidney Transplantation for Focal Segmental Glomerulosclerosis: Can We Prevent Its Recurrence? Personal Experience and Literature Review
por: Naciri Bennani, Hamza, et al.
Publicado: (2021)

Very Early Severe Posttransplant Recurrent Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis after Kidney Transplantation: Two Case Reports
por: Laamech, Reda, et al.
Publicado: (2022)

Apheresis Efficacy and Tolerance in the Setting of HLA-Incompatible Kidney Transplantation
por: Noble, Johan, et al.
Publicado: (2021)

Cryoglobulinemia and double‐filtration plasmapheresis: Personal experience and literature review
por: Naciri Bennani, Hamza, et al.
Publicado: (2022)

Opportunistic Infections and Efficacy Following Conversion to Belatacept-Based Therapy after Kidney Transplantation: A French Multicenter Cohort
por: Bertrand, Dominique, et al.
Publicado: (2020)

Early Blood Transfusion After Kidney Transplantation Does Not Lead to dnDSA Development: The BloodIm Study
por: Jouve, Thomas, et al.
Publicado: (2022)

Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review
por: Cabezas, Lara, et al.
Publicado: (2022)

Apheresis Therapy for Steroid-Resistant Idiopathic Nephrotic Syndrome: Report on a Case Series
por: Naciri Bennani, Hamza, et al.
Publicado: (2019)

Marginal Impact of Tocilizumab Monotherapy on Anti-HLA Alloantibodies in Highly Sensitized Kidney Transplant Candidates
por: Daligault, Mélanie, et al.
Publicado: (2021)

Immortal Time-Bias–Corrected Survival of Highly Sensitized Patients and HLA-desensitized Kidney Transplant Recipients
por: Noble, Johan, et al.
Publicado: (2021)

Tocilizumab Evaluation in HLA-Desensitization before Kidney Transplantation as an Add-On Therapy to Apheresis: The TETRA Study
por: Jouve, Thomas, et al.
Publicado: (2023)

Tocilizumab in the Treatment of Chronic Antibody-Mediated Rejection Post Kidney Transplantation: Clinical and Histological Monitoring
por: Noble, Johan, et al.
Publicado: (2021)

Transplantation of Marginal Organs: Immunological Aspects and Therapeutic Perspectives in Kidney Transplantation
por: Noble, Johan, et al.
Publicado: (2020)

Efficacy of Plasmapheresis in Nivolumab-Associated ANCA Glomerulonephritis: A Case Report and Pathophysiology Discussion
por: Laamech, Reda, et al.
Publicado: (2021)

Immune Response Post–SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept
por: Noble, Johan, et al.
Publicado: (2021)

A Case of Pneumocystis jirovecii Pneumonia under Belatacept and Everolimus: Benefit-Risk Balance between Renal Allograft Function and Infection
por: Perrier, Quentin, et al.
Publicado: (2021)

Tocilizumab and Desensitization in Kidney Transplant Candidates: Personal Experience and Literature Review
por: Weinhard, Jules, et al.
Publicado: (2021)

Costimulation Blockade in Kidney Transplantation: An Update
por: Malvezzi, Paolo, et al.
Publicado: (2016)

Conversion to mTOR-Inhibitors Plus IV Immunoglobulins in Kidney-Transplant Recipients with BKV Infection: A Retrospective Comparative Study
por: Vela, Carla, et al.
Publicado: (2022)

Place of mTOR inhibitors in management of BKV infection after kidney transplantation
por: Jouve, Thomas, et al.
Publicado: (2016)

Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage
por: Malvezzi, Paolo, et al.
Publicado: (2015)

Negative Impact of CMV and BKV Infections on Kidney-Allograft Function at 1-Year Post-Transplantation: Can it Be Changed by Modifying Immunosuppression?
por: Malvezzi, Paolo, et al.
Publicado: (2018)

Early post-transplant complications following ABO-incompatible kidney transplantation
por: Naciri Bennani, Hamza, et al.
Publicado: (2016)

Tocilizumab Trough Levels Variability in Kidney-Transplant Candidates Undergoing Desensitization
por: Truffot, Aurélie, et al.
Publicado: (2021)

Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate
por: Belliere, Julie, et al.
Publicado: (2014)

Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients
por: El Sakhawi, Karim, et al.
Publicado: (2020)

Belatacept Conversion in Kidney After Liver Transplantation
por: Cristea, Octav, et al.
Publicado: (2021)

Early Exposure of Kidney Transplant Recipients with Chronic Antibody-Mediated Rejection to Tocilizumab—A Preliminary Study
por: Arrivé, Capucine, et al.
Publicado: (2023)

Belatacept and mediastinal histoplasmosis in a kidney transplant patient
por: Trimarchi, Hernán, et al.
Publicado: (2016)

Belatacept in kidney transplant patients with systemic lupus erythematosus
por: Carrión-Barberà, Irene, et al.
Publicado: (2019)

Time-Limited Therapy with Belatacept in Kidney Transplant Recipients
por: Letellier, Thibault, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
por: Tawhari, Ibrahim, et al.
Publicado: (2022)

Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept
por: Pernin, Vincent, et al.
Publicado: (2022)

Ten Years Experience With Belatacept-Based Immunosuppression After Kidney Transplantation
por: Grannas, Gerrit, et al.
Publicado: (2014)

De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019)

Belatacept in Kidney Transplantation: What Are the True Benefits? A Systematic Review
por: Lombardi, Yannis, et al.
Publicado: (2022)

Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept
por: Schwarz, Chloë, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9igqnpproa7f36s3j4moe85av6